Financière de Tubize SA (TUB.BR)

EUR 132.8

(5.23%)

Operating Expenses Summary of Financière de Tubize SA

  • Financière de Tubize SA's latest annual operating expenses in 2023 was 114.38 Thousand EUR , up 2263.59% from previous year.
  • Financière de Tubize SA's latest quarterly operating expenses in 2024 Q2 was 20.51 Thousand EUR , down 0.0% from previous quarter.
  • Financière de Tubize SA reported a annual operating expenses of -5287.00 EUR in annual operating expenses 2022, down -100.34% from previous year.
  • Financière de Tubize SA reported a annual operating expenses of 1.53 Million EUR in annual operating expenses 2021, down -31.79% from previous year.
  • Financière de Tubize SA reported a quarterly operating expenses of 900.65 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.
  • Financière de Tubize SA reported a quarterly operating expenses of 258.38 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Financière de Tubize SA (2023 - 2003)

Historical Annual Operating Expenses of Financière de Tubize SA (2023 - 2003)

Year Operating Expenses Operating Expenses Growth
2023 114.38 Thousand EUR 2263.59%
2022 -5287.00 EUR -100.34%
2021 1.53 Million EUR -31.79%
2020 2.24 Million EUR -99.21%
2019 284.88 Million EUR 29855.84%
2018 951 Thousand EUR 1.17%
2017 940 Thousand EUR 38.85%
2016 677 Thousand EUR 13.97%
2015 594 Thousand EUR -8.33%
2014 648 Thousand EUR -20.3%
2013 813 Thousand EUR 94.5%
2012 418 Thousand EUR 12.37%
2011 372 Thousand EUR 1.92%
2010 365 Thousand EUR -7.83%
2009 396 Thousand EUR 178.11%
2008 -507 Thousand EUR -397.06%
2007 -102 Thousand EUR -109.6%
2006 1.06 Million EUR -24.13%
2005 1.4 Million EUR 283.84%
2004 365 Thousand EUR -96.59%
2003 10.69 Million EUR 0.0%

Peer Operating Expenses Comparison of Financière de Tubize SA

Name Operating Expenses Operating Expenses Difference
Nicox S.A. -11.5 Million EUR 100.994%
European Medical Solutions 13.64 Million EUR 99.162%
FERMENTALG 12.34 Million EUR 99.073%
argenx SE 1.34 Billion EUR 99.991%
BioSenic S.A. 7.58 Million EUR 98.492%
Celyad Oncology SA 8.49 Million EUR 98.653%
Hyloris Pharmaceuticals SA 17.98 Million EUR 99.364%
Onward Medical N.V. 20.64 Million EUR 99.446%
Oxurion NV 12.21 Million EUR 99.063%
PHAXIAM Therapeutics S.A. 24.98 Million EUR 99.542%
UCB SA 2.94 Billion EUR 99.996%